共 50 条
- [41] Real-world Use of Radiation for Newly Diagnosed Brain Metastases in Patients With ALK-positive Lung Cancer Receiving First-line ALK InhibitorINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (04): : 627 - 634Kumar, SameeraWang, XiaoliangPittell, HarlanCalip, Gregory S.Weiss, Stephanie E.Meyer, Joshua E.Royce, Trevor J.
- [42] First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-AnalysisJOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)Wu, Kuan-LiChen, Hsiao-LingTsai, Ying-MingLee, Tai-HuangChang, Hsiu-MeiTsai, Yu-ChenChuang, Cheng-HaoChang, Yong-ChiehTu, Yu-KangYang, Chih-JenHung, Jen-YuChong, Inn-Wen
- [43] First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK plus ) NonSmall Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S584 - S584Shaw, A.Bauer, T.Takahashi, T.Balk, C.Goto, Y.Polli, A.Carpentieri, M.Martini, J.Solomon, B.
- [44] Experience with First Line Crizotinib in ALK Positive Lung Cancer Patients, Instituto Oncologico Nacional - PanamaJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S167 - S167Arauz, E.Vergara, R.Sowley, T.
- [45] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancerREVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116Toffart, A. -C.Sakhri, L.Moro-Sibilot, D.
- [46] Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN studyANNALS OF ONCOLOGY, 2020, 31 : S1180 - S1181Solomon, B.Bauer, T. M.De Marinis, F.Felip, E.Goto, Y.Liu, G.Mazieres, J.Kim, D-W.Mok, T.Polli, A.Thurm, H.Calella, A. M.Peltz, G.Shaw, A.
- [47] Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLCJTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (05):Zhou, QingSoo, Ross A.Chang, Gee-ChenChiu, Chao-HuaHayashi, HidetoshiKim, Sang-WeTeraoka, ShunsukeGoto, YasushiZhou, JianyingLee, Victor Ho-FunKim, Dong-WanHan, BaohuiHo, James Chung ManLin, Chia-ChiLu, ShunPolli, AnnaCalella, Anna MariaMartini, Jean-FrancoisWong, Chew HooiMok, TonyKim, Hye RyunWu, Yi-Long
- [48] Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung CancerJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1539 - 1548Wu, Yi-LongLu, ShunLu, YouZhou, JianyingShi, Yuan-kaiSriuranpong, ViroteHo, James C. M.Ong, Choo KhoonTsai, Chun-MingChung, Chin-HeeWilner, Keith D.Tang, YiyunMasters, Elizabeth T.Selaru, PaulinaMok, Tony S.
- [49] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerNEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 829 - 838Peters, SolangeCamidge, D. RossShaw, Alice T.Gadgeel, ShirishAhn, Jin S.Kim, Dong-WanOu, Sai-Hong I.Perol, MauriceDziadziuszko, RafalRosell, RafaelZeaiter, AliMitry, EmmanuelGolding, SophieBalas, BogdanaNoe, JohannesMorcos, Peter N.Mok, Tony